Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition

Inclusion Criteria: * Healthy male and female subjects * Aged 18-55 years inclusive * A body mass index in the range of 18-25 kg/m2 * Able to participate, communicate well with the investigators and willing to give informed consent * Non-smokers * Vital signs (after 10 minutes resting) are within the following ranges: * systolic blood pressure 100-125 mmHg * diastolic blood pressure 60-80 mmHg * pulse rate 60-90 bpm Exclusion Criteria: * Pregnant or lactating women * Known hypersensitivity or contraindication to perindopril * Intake of any prescription drug within 14 days of this study's first dosing day * Intake of any non-prescription drug, food supplement, or herbal medicine within 7 days of this study's first dosing day * History or presence of any liver dysfunction (ALT, alkaline phosphatase, total bilirubin ≥ 1.5 ULN) * History of any bleeding or coagulation disorders * Clinically significant ECG abnormalities * Clinically significant haematology abnormalities * Renal insufficiency (plasma creatinine concentration ≥ 1.4 mg/dL) * Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the study drug * A donation or loss of 500 mL (or more) of blood within 3 months before this study's first dosing day * A positive hepatitis B surface antigen (HBsAg), anti-HCV, and anti-HIV * History of drug or alcohol abuse within 12 months prior to screening of this study * Participation in a previous study within 3 months of this study's first dosing day